Top 10 Pitfalls of Participating in the 340B Drug Pricing Program 2016

Health Care

March 07, 2016
by Vicki Mueller, CPA

Bookmark and Share
Vicki Mueller Vicki Mueller, CPA
Director

View Profile
 
 

Given today’s declining reimbursement landscape, most health care organizations are engaging in additional cost-saving strategies. The federal 340B Drug Pricing Program is one such opportunity that is available to critical access hospitals (CAHs), disproportionate share hospitals (DSHs), and other eligible covered entities. Whether an entity already participates in the 340B program or is considering it, it’s important to understand the compliance risks and overall program challenges. Here are the top pitfalls to avoid to help ensure a well-run program.


Average Rating:

Length: 1 pages (PDF 139 kB)



Rate this Article
*  =  required fields
Your Rating*
Name*
E-mail Address*
Company